Motor adverse effects were observed at doses above 0.1 mg/kg, limiting administration of higher doses, and were most likely attributable to activity at NaV1.6, which is expressed in the periphery on sensory and motor neurons, where loss of function leads to movement disorders and hind limb paralysis [34]. Here, SCN8A is linked to movement disorder.